Abraham Viju Ipe, Lewis J. Fermaglich, Selma Kraft, Catherine Mease, Tran Le, Kathleen L. Miller
{"title":"孤儿药法案》与罕见癌症:1983-2022 年肿瘤孤儿药指定及相关批准的回顾性分析","authors":"Abraham Viju Ipe, Lewis J. Fermaglich, Selma Kraft, Catherine Mease, Tran Le, Kathleen L. Miller","doi":"10.1080/21678707.2024.2333245","DOIUrl":null,"url":null,"abstract":"Rare cancers account for approximately 1 in 8 of all cancers diagnosed in the United States (US) every year. Remarkable scientific advances in cancer research over the past 40 years, in addition to...","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022\",\"authors\":\"Abraham Viju Ipe, Lewis J. Fermaglich, Selma Kraft, Catherine Mease, Tran Le, Kathleen L. Miller\",\"doi\":\"10.1080/21678707.2024.2333245\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rare cancers account for approximately 1 in 8 of all cancers diagnosed in the United States (US) every year. Remarkable scientific advances in cancer research over the past 40 years, in addition to...\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21678707.2024.2333245\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678707.2024.2333245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022
Rare cancers account for approximately 1 in 8 of all cancers diagnosed in the United States (US) every year. Remarkable scientific advances in cancer research over the past 40 years, in addition to...